^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
DRUG:

PT886

i
Other names: PT886, PT-886, PT 886
Associations
Company:
Phanes Therap
Drug class:
CD47 inhibitor, CLDN18.2 inhibitor
Related drugs:
Associations
9ms
Enrollment change
|
CLDN18 (Claudin 18)
|
HER-2 overexpression • CLDN18.2 expression
|
Keytruda (pembrolizumab) • gemcitabine • 5-fluorouracil • capecitabine • albumin-bound paclitaxel • oxaliplatin • leucovorin calcium • PT886
10ms
PT886 For Treatment of Patients With Metastatic/Advanced Gastric, Gastroesophageal Junction and Pancreatic Adenocarcinoma (the TWINPEAK Study) (clinicaltrials.gov)
P1/2, N=72, Recruiting, Phanes Therapeutics | Phase classification: P1 --> P1/2 | Trial completion date: Apr 2024 --> Apr 2026 | Trial primary completion date: Nov 2023 --> Dec 2025
Phase classification • Trial completion date • Trial primary completion date • Combination therapy • Metastases
|
CLDN18 (Claudin 18)
|
HER-2 overexpression • CLDN18.2 expression
|
gemcitabine • albumin-bound paclitaxel • PT886
almost2years
PT886 For Treatment of Patients With Advanced Gastric, Gastroesophageal Junction and Pancreatic Adenocarcinomas (clinicaltrials.gov)
P1, N=58, Recruiting, Phanes Therapeutics | Not yet recruiting --> Recruiting | Trial completion date: Jan 2024 --> Apr 2024 | Initiation date: Aug 2022 --> Nov 2022 | Trial primary completion date: Aug 2023 --> Nov 2023
Enrollment open • Trial completion date • Trial initiation date • Trial primary completion date • Metastases
|
CLDN18 (Claudin 18)
|
HER-2 overexpression
|
PT886
over2years
New P1 trial
|
CLDN18 (Claudin 18)
|
HER-2 overexpression
|
PT886
over2years
PT886, an anti-claudin18.2/anti-CD47 bispecific antibody constructed with the PACbodyTM and SPECpairTM technology platforms, exhibits robust anti-tumor activity in a pancreatic cancer xenograft model (AACR 2022)
These data support the proof of concept of the PACbody™ and SPECpair™ technology platforms and demonstrate the unique profile of our anti-CD47 arm that’s suitable for the bispecific antibody approach. PT886 is a first-in-class anti-CLDN18.2/anti-CD47 bispecific antibody with native IgG-like structure and phase 1 clinical trial is planned for the first quarter of 2022.
Preclinical
|
CLDN18 (Claudin 18) • CD47 (CD47 Molecule) • CLDN8 (Claudin 8) • SIRPA (Signal Regulatory Protein Alpha)
|
CLDN18.2 expression • CLDN18.2 overexpression
|
PT886